Jaguar Animal Health, Inc. — Q1 2017 Form 10-Q
Reporting period: Three months ended March 31, 2017. Financial statements are unaudited. The filing describes an animal-health company developing and commercializing gastrointestinal products for animals.
Financial performance and position
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Total revenue | $822,410 | $38,146 |
| Operating expenses | $4,698,012 | $3,722,907 |
| Loss from operations | $(3,875,602) | $(3,684,761) |
| Net loss | $(4,715,358); $(0.33) per share | $(3,984,204); $(0.43) per share |
| Cash used in operations | $(288,720) | $(4,527,858) |
| Cash and cash equivalents, March 31 | $1,205,061 | — |
- Revenue included $74,544 of product revenue—$44,544 from Neonorm and $30,000 from botanical extract—and $747,866 of Elanco collaboration revenue. The latter included upfront-payment revenue recognized over an estimated one-year development period and reimbursable expenses.
- General and administrative expense rose 84.7% to $3.30 million, principally due to merger-related costs. Research and development expense declined 28.3% to $1.26 million, partly reflecting lower manufacturing and clinical spending; sales and marketing expense declined 25.2% to $123,000.
- Cash increased by $254,082 during the quarter. Operating cash use was offset by a $490,101 release of restricted cash and $542,802 net proceeds from the CSPA, less debt repayment. The remaining $21,192 of restricted cash was released on April 1, 2017.
- At March 31, current assets were $2.58 million and current liabilities were $8.43 million. Stockholders’ deficit was $6.19 million, and accumulated deficit was $45.15 million.
- Net long-term debt was $3.33 million, including $1.99 million classified as current; a separate $150,000 convertible note was also outstanding. Long-term debt carried a 9.9% contractual rate, with a stated 15.0% effective rate reflecting fees and the end-of-term payment. The filing reports a $560,000 end-of-term payment due in 2018.
Material changes and significant developments
- Revenue increased sharply from the new Elanco agreement, signed January 27, 2017; product revenue also increased from the prior-year quarter. Net loss nevertheless widened by $731,154.
- The Elanco agreement provides an upfront payment of approximately $2.55 million, up to $61 million in potential development, regulatory and sales milestones, expense reimbursement, and royalties. Elanco has exclusive global rights outside the U.S. and co-exclusive U.S. rights for covered products. Milestone amounts are contingent, not guaranteed revenue.
- Jaguar entered a definitive merger agreement with former parent Napo on March 31, 2017. The proposed transaction includes a 3-to-1 Napo-to-Jaguar value ratio and substantial issuance of shares to Napo creditors and other holders. Management estimated pre-merger Jaguar holders would own approximately 25% of the combined company on a fully diluted basis, implying approximately 75% dilution.
- The merger is subject to conditions including shareholder approvals and an effective Form S-4. If it does not close by July 31, 2017, under specified circumstances Jaguar must issue Napo 2 million restricted shares. A conditional $3 million Invesco investment at $0.925 per share is to be loaned to Napo in connection with the merger and debt settlement.
- A warrant fair-value increase of $453,419 and a $207,713 debt-extinguishment loss were recorded in Q1; both increased reported loss and were associated with noncash accounting effects. Merger-related professional and other fees were approximately $1.75 million through March 31.
Outlook, risks and contingencies
- Management stated that existing cash was insufficient for anticipated needs over the next 12 months and would not fund the operating plan through March 2018. The filing says recurring losses, future spending needs and dependence on additional financing raise substantial doubt about the company’s ability to continue as a going concern.
- The company expects further losses and increased spending in 2017 for product development, regulatory studies, manufacturing and commercialization. It may need additional equity, debt or collaboration financing; availability and terms are uncertain, and financing could dilute shareholders or impose repayment obligations and covenants. No specific financial guidance was provided.
- Canalevia’s pivotal field study for acute diarrhea in dogs completed enrollment of 200 dogs in January 2017. Management expected to pursue a CID commercial launch in the following year; approval and launch remain subject to regulatory and development progress. Equilevia completed a dose-determination study, and the company entered a 60-day evaluation period with a potential partner beginning April 3, 2017.
- Key risks include clinical and regulatory outcomes, ability to finance operations, merger completion and integration, potential dilution, dependence on collaborators and distributors, and variability in revenue recognition estimates. The company reported no material legal proceedings and stated disclosure controls were effective.
Investor facts to verify
- Cash runway, actual subsequent financing, and the status and terms of any CSPA share sales and approvals.
- Merger closing conditions, final debt settlement and financing arrangements, share issuance, dilution, and any failure-to-close consequences.
- Canalevia study results, regulatory pathway and launch timing; Equilevia evaluation outcome; and achievement of any Elanco milestones.
- Debt repayment schedule and ability to meet near-term obligations, including the 2018 end-of-term payment.
- Reconciliation of merger-related expenses and deferred Elanco revenue, including the timing of recognition and collection of reimbursable costs.